Literature DB >> 23060923

Adrenal tumor volume in a genetically engineered mouse model of neuroblastoma determined by magnetic resonance imaging.

Kumi Kawano1, Yoshiyuki Hattori, Hiroshi Iwakura, Takashi Akamizu, Yoshie Maitani.   

Abstract

Neuroblastoma is the second most common type of solid tumor in children and is commonly found in the adrenal medulla. Recently, we developed transgenic mice exhibiting tumors bilaterally in the adrenal medulla through the expression of SV40 T-antigen. Since these transgenic mice facilitate the development of new therapeutic approaches for neuroblastoma, non-invasive monitoring methods are required for serial measurement of tumor progression. In this study, we monitored the serial progression of adrenal tumors in transgenic mice by magnetic resonance imaging (MRI) of 9.4 T vertical type, and calculated the tumor volume. The accuracy of the tumor volume determination by MRI was verified by standard volume measurements at autopsy. Adrenal tumors as small as 1.5 mm in diameter were detected and quantitatively measured in the transgenic mice by in vivo MRI without using exogenous contrast agents on T(2)-weighted spin echo images. The tumor sizes by MRI correlated better with tumor weight than the volume by calculation with a caliper. Furthermore, we monitored the change of tumor volume following administration of doxorubicin at weekly intervals. The tumor progression and regression following doxorubicin treatment in the individual mice could be observed by serial MRI. From these findings, non-invasive MRI is likely to be useful for monitoring the response of spontaneous tumors to therapeutic drugs.

Entities:  

Year:  2012        PMID: 23060923      PMCID: PMC3460253          DOI: 10.3892/etm.2012.564

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  12 in total

1.  Magnetic resonance imaging for the evaluation of a novel metastatic orthotopic model of human neuroblastoma in immunodeficient mice.

Authors:  R Moats; L Q Ma; R Wajed; Y Sugiura; A Lazaryev; M Tyszka; R Jacobs; S Fraser; M D Nelson; Y A DeClerck
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Magnetic resonance imaging to measure therapeutic response using an orthotopic model of human pancreatic cancer.

Authors:  Z He; J L Evelhoch; R M Mohammad; N V Adsay; G R Pettit; V K Vaitkevicius; F H Sarkar
Journal:  Pancreas       Date:  2000-07       Impact factor: 3.327

3.  Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.

Authors:  Anna Degrassi; Micaela Russo; Cristina Nanni; Veronica Patton; Rachele Alzani; Anna M Giusti; Stefano Fanti; Marina Ciomei; Enrico Pesenti; Gemma Texido
Journal:  Mol Cancer Ther       Date:  2010-03-02       Impact factor: 6.261

Review 4.  Murine models to evaluate novel and conventional therapeutic strategies for cancer.

Authors:  James E Talmadge; Rakesh K Singh; Isaiah J Fidler; Avraham Raz
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

5.  Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.

Authors:  Denise C Connolly; Rudi Bao; Alexander Yu Nikitin; Kasie C Stephens; Timothy W Poole; Xiang Hua; Skye S Harris; Barbara C Vanderhyden; Thomas C Hamilton
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

6.  Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer.

Authors:  Harvey Hensley; Bridget A Quinn; Ronald L Wolf; Samuel L Litwin; Seiji Mabuchi; Stephen J Williams; Christine Williams; Thomas C Hamilton; Denise C Connolly
Journal:  Cancer Biol Ther       Date:  2007-08-03       Impact factor: 4.742

7.  High-resolution longitudinal screening with magnetic resonance imaging in a murine brain cancer model.

Authors:  Nicholas A Bock; Gelareh Zadeh; Lori M Davidson; Baoping Qian; John G Sled; Abhijit Guha; R Mark Henkelman
Journal:  Neoplasia       Date:  2003 Nov-Dec       Impact factor: 5.715

Review 8.  Neuroblastoma.

Authors:  John M Maris; Michael D Hogarty; Rochelle Bagatell; Susan L Cohn
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

9.  In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model.

Authors:  Libo Zhang; Kristen M Smith; Amy L Chong; Diana Stempak; Herman Yeger; Paula Marrano; Paul S Thorner; Meredith S Irwin; David R Kaplan; Sylvain Baruchel
Journal:  Neoplasia       Date:  2009-05       Impact factor: 5.715

10.  Establishment of a novel neuroblastoma mouse model.

Authors:  Hiroshi Iwakura; Hiroyuki Ariyasu; Naotetsu Kanamoto; Kiminori Hosoda; Kazuwa Nakao; Kenji Kangawa; Takashi Akamizu
Journal:  Int J Oncol       Date:  2008-12       Impact factor: 5.650

View more
  7 in total

1.  Lithium Ascorbate as a Promising Neuroprotector: Fundamental and Experimental Studies of an Organic Lithium Salt.

Authors:  Ivan Yu Torshin; Olga A Gromova; Konstantin S Ostrenko; Marina V Filimonova; Irina V Gogoleva; Vladimir I Demidov; Alla G Kalacheva
Journal:  Molecules       Date:  2022-03-30       Impact factor: 4.411

2.  SUSD2 promotes tumor-associated macrophage recruitment by increasing levels of MCP-1 in breast cancer.

Authors:  Elizabeth M Hultgren; Mitch E Patrick; Rick L Evans; Catherine T Stoos; Kristi A Egland
Journal:  PLoS One       Date:  2017-05-05       Impact factor: 3.240

3.  Inositol 1, 4, 5-trisphosphate-dependent nuclear calcium signals regulate angiogenesis and cell motility in triple negative breast cancer.

Authors:  Erika Guimarães; Rodrigo Machado; Matheus de Castro Fonseca; Andressa França; Clarissa Carvalho; Ana Cândida Araújo E Silva; Brígida Almeida; Puebla Cassini; Bárbara Hissa; Luciana Drumond; Carlos Gonçalves; Gabriel Fernandes; Marina De Brot; Márcio Moraes; Lucíola Barcelos; José Miguel Ortega; André Oliveira; M Fátima Leite
Journal:  PLoS One       Date:  2017-04-04       Impact factor: 3.240

4.  Combination therapy with gefitinib and doxorubicin inhibits tumor growth in transgenic mice with adrenal neuroblastoma.

Authors:  Kumi Kawano; Yoshiyuki Hattori; Hiroshi Iwakura; Takashi Akamizu; Yoshie Maitani
Journal:  Cancer Med       Date:  2013-04-02       Impact factor: 4.452

5.  Evaluation of Nonradiative Clinical Imaging Techniques for the Longitudinal Assessment of Tumour Growth in Murine CT26 Colon Carcinoma.

Authors:  Johanne Seguin; Bich-Thuy Doan; Heldmuth Latorre Ossa; Lauriane Jugé; Jean-Luc Gennisson; Mickaël Tanter; Daniel Scherman; Guy G Chabot; Nathalie Mignet
Journal:  Int J Mol Imaging       Date:  2013-07-02

6.  Surface α-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target.

Authors:  Kuan-Chung Hsiao; Neng-Yao Shih; Hsun-Lang Fang; Tze-Sing Huang; Ching-Chuan Kuo; Pei-Yi Chu; Yi-Mei Hung; Shao-Wen Chou; Yi-Yuan Yang; Gee-Chen Chang; Ko-Jiunn Liu
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

7.  Similarity on neural stem cells and brain tumor stem cells in transgenic brain tumor mouse models.

Authors:  Guanqun Qiao; Qingquan Li; Gang Peng; Jun Ma; Hongwei Fan; Yingbin Li
Journal:  Neural Regen Res       Date:  2013-09-05       Impact factor: 5.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.